Adamas Pharmaceuticals $59 million stock offering
We advised the joint book-running managers on the SEC-registered equity offering
3/1/2021

Davis Polk advised the joint book-running managers in connection with a $59 million SEC-registered follow-on offering of 14,375,000 shares of common stock by Adamas Pharmaceuticals, Inc., which included shares sold pursuant to a full exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the Nasdaq Global Market under the symbol “ADMS.”

Adamas is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological disorders.

The Davis Polk corporate team included partner Emily Roberts and associates Dongbiao Shen and Alex DeGroat. The intellectual property and technology transactions team included partner David R. Bauer and associate Brette L. Trost. The tax team included partner Mario J. Verdolini and associate Tomislava Dragicevic. Members of the Davis Polk team are based in the Northern California and New York offices.